Botox by Allergan: UK product information

12 August 2026
Tom van Eijk
The contents of this article is medically checked by: Drs. Tom van Eijk

BOTOX is a prescription-only medicine containing botulinum toxin type A. It was developed and marketed by Allergan, which became part of the pharmaceutical company AbbVie in 2020.

In the UK, the medicine is listed in official product information under the name BOTOX. Vistabel is a related trade name used in several European countries, but medicine names and authorised indications can differ between markets.

This distinction is important because not all botulinum toxin medicines are interchangeable. Each product has its own authorised uses, dosing instructions and safety information.

This page explains what Allergan Botox is, how the medicine works, its relationship with Vistabel and the UK information patients should know.

For a broader explanation of the treatment category, read the Botox overview.

Botox by Allergan: UK product information

What is Allergan Botox and how does it work?

Allergan Botox refers to BOTOX, a branded medicine containing botulinum toxin type A.

Botulinum toxin type A acts at the connection between nerves and muscles. It temporarily reduces the release of acetylcholine, a chemical messenger involved in muscle contraction. As a result, the affected muscle becomes less active for a period of time.

BOTOX has authorised uses for certain medical conditions and specified cosmetic indications. The appropriate use depends on the medicine's product information and an individual clinical assessment.

The effects are temporary, but the duration varies according to the indication and other factors. It is not appropriate to assume that every treatment using botulinum toxin has the same expected results or duration.

Different botulinum toxin products also have their own dosing systems. A unit of one preparation must not automatically be treated as equivalent to a unit of another.

Is Allergan Botox the same as Vistabel?

BOTOX and Vistabel are product names associated with botulinum toxin type A medicines developed by Allergan.

Vistabel has been used as a trade name for an aesthetic botulinum toxin medicine in several European countries. BOTOX is the name listed for the relevant AbbVie product in current UK medicines information.

Although these names are related, they should not automatically be treated as interchangeable across countries. Product authorisations, indications and prescribing information must be considered for the specific medicine and market.

For UK patients, the most useful information is the exact product name, its UK authorisation and the intended clinical use. A healthcare professional should be able to identify the medicine being considered and explain its product-specific information.

The term “Botox” is also frequently used informally to describe botulinum toxin injections in general. However, BOTOX is a specific branded medicine, and other preparations are separately authorised products.

Who makes BOTOX?

BOTOX was developed and marketed by Allergan. On 8 May 2020, AbbVie completed its acquisition of Allergan, bringing Allergan's pharmaceutical and aesthetic medicine portfolio into the AbbVie group.

According to the UK BOTOX patient information leaflet, AbbVie Ltd is the marketing authorisation holder and Allergan Pharmaceuticals Ireland is the manufacturer.

The manufacturer is located in Westport, County Mayo, Ireland.

When checking information about a medicine, the current UK patient information leaflet and Summary of Product Characteristics are more relevant than historical company information. They identify the medicine and provide important details about its authorised uses, precautions and safety information.

Is Allergan Botox authorised in the UK?

BOTOX is an authorised prescription-only medicine in the UK. Its permitted uses, prescribing instructions and precautions are described in the relevant UK product information.

The medicine has specified medical and cosmetic indications. An authorisation for one condition or treatment area does not mean that every proposed use of botulinum toxin is licensed.

Different botulinum toxin medicines may have different indications, dose units and product information. This means that a treatment authorised for one product should not automatically be assumed to be authorised for another.

Product authorisations can also differ between countries. For example, approval by the United States Food and Drug Administration does not establish whether a medicine or particular indication is authorised in the United Kingdom.

Patients can consult the official UK patient information leaflet for information about the medicine. Healthcare professionals should refer to the relevant Summary of Product Characteristics for prescribing information.

The exact medicine, intended use and any relevant limitations should be explained during an individual clinical assessment.

What should patients know about safety and prescribing?

BOTOX is a prescription-only medicine. Its suitability depends on the clinical indication, medical history and individual circumstances.

Possible adverse effects vary according to the treatment area and product. These can include injection-site discomfort, bruising or swelling, as well as unwanted weakness of nearby muscles. The official product information also describes less common but potentially serious reactions.

Rare symptoms involving difficulty swallowing, speaking or breathing after botulinum toxin treatment require urgent medical attention.

Before any treatment decision, patients should have an appropriate assessment and receive clear information about the proposed medicine, potential risks and available alternatives.

Useful questions to discuss with a healthcare professional include:

  • What is the exact name of the medicine?

  • Is it authorised for use in the UK?

  • What condition or concern is it being considered for?

  • Is the proposed use within its licensed indication?

  • Who will prescribe and administer it?

  • What relevant qualifications and experience does the practitioner have?

  • What risks, limitations and alternatives should be considered?

  • What follow-up arrangements are available if complications occur?

A prescription medicine should not be selected solely because of a brand name or a comparison of advertised prices. Treatment decisions should follow an individual clinical assessment, and choosing not to proceed remains an option.

Compare clinics for botulinum toxin treatments

Compare on experience & price Make an appointment immediately

Why Injectablesbooking.co.uk

All clinics in United Kingdom
Read reviews and compare prices
Compare specialists on experience and quality
Always nearby you